94,009 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 94,009 shares of the biopharmaceutical company's stock, valued at approximately $5,381,000. Caisse DE Depot ET Placement DU Quebec owned approximately 0.07% of Halozyme Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of HALO. Congress Asset Management Co. raised its stake in Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock worth $99,363,000 after purchasing an additional 209,530 shares during the period. American Century Companies Inc. boosted its position in Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock valued at $43,002,000 after buying an additional 72,544 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in Halozyme Therapeutics by 37.8% in the 2nd quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company's stock worth $36,449,000 after buying an additional 191,030 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In other news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $39,988,802.96. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 60,000 shares of company stock valued at $3,425,000. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded down $0.11 on Tuesday, reaching $48.48. The company's stock had a trading volume of 1,177,171 shares, compared to its average volume of 1,371,395. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $6.17 billion, a P/E ratio of 16.05, a PEG ratio of 0.44 and a beta of 1.23. The stock has a 50-day moving average price of $53.08 and a 200-day moving average price of $53.82. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Benchmark reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. TD Cowen lifted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.